Vicarious Surgical Inc Stock Price, News & Analysis

Vicarious Surgical (NYSE: RBOT) reported its Q2 2025 financial results, marking a significant transition in leadership as Adam Sachs moves to President and Stephen From takes over as CEO. The surgical robotics company reported a GAAP net loss of $13.2 million ($2.23 per share), improving from a $15.2 million loss in Q2 2024.

Operating expenses decreased 24% to $13.5 million, with R&D expenses at $9.1 million, G&A at $4.1 million, and sales/marketing at $0.3 million. The company ended Q2 with $24.0 million in cash and investments, reporting a quarterly cash burn of $13.4 million. Management projects full-year 2025 cash burn of approximately $50 million.

[ "Net loss improved from $15.2M in Q2 2024 to $13.2M in Q2 2025", "Operating expenses reduced by 24% year-over-year", "Sales and marketing expenses decreased significantly from $1.2M to $0.3M" ]

Vicarious Surgical (NYSE: RBOT) has appointed Stephen From as its new Chief Executive Officer and Board member, effective August 7, 2025. Current CEO and Co-Founder Adam Sachs will transition to the role of President while remaining on the Board. From brings over 20 years of healthcare and financial industry leadership experience, most recently serving as CEO of Aruna Bio.

From's extensive background includes serving as President, CEO, and Executive Chairman of Kiora Pharmaceuticals, where he led the company through its IPO and multiple acquisitions. He previously held positions as CFO of Centelion SAS and worked in investment banking at Bank of America Securities and Robertson Stephens.

As part of his appointment, From will receive a stock option award for 297,600 shares of Class A common stock, vesting over four years, as a material inducement to his employment.

Vicarious Surgical (NYSE: RBOT), a next-generation robotics technology company focused on transforming robotic surgery, has scheduled its Q2 2025 financial results announcement for August 12, 2025, after market close.

The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors can join via phone using the following details: domestic callers: +1 833-470-1428, international callers: +1 404-975-4839, access code: 572850. A webcast will be available on the company's investor relations website.

Vicarious Surgical (NYSE: RBOT) reported its Q1 2025 financial results, marking progress towards becoming a clinical-stage company. The company posted a GAAP net loss of $15.4 million ($2.60 per share), compared to $17.0 million loss in Q1 2024. Operating expenses decreased 2% to $15.7 million, with R&D expenses at $9.4 million, G&A expenses at $5.3 million, and sales/marketing costs at $1.0 million. The company maintained $37.4 million in cash and investments as of March 31, 2025, with a Q1 cash burn rate of $11.7 million. Management projects full-year 2025 cash burn of approximately $50 million. CEO Adam Sachs highlighted the company's approaching milestone of treating first clinical patients and progress in procurement and manufacturing efforts for their single-port surgical system.

Vicarious Surgical (NYSE: RBOT) has announced a strategic collaboration with UMass Memorial Medical Center, the largest not-for-profit hospital in Central Massachusetts. The partnership aims to support the adoption and utilization of Vicarious Surgical's robotic surgery system through various initiatives.

The collaboration will focus on streamlining operational aspects including inventory management, sterilization protocols, and standardization of pre and post-procedure processes. It will also encompass case observation for surgeons, system testing, research development insights, peer-to-peer education, and best practices promotion.

UMass Memorial Medical Center, with 826 licensed beds, serves as the clinical partner of the University of Massachusetts Chan Medical School and will work directly with Vicarious Surgical's team to refine and validate best practices in robotic surgery.

Vicarious Surgical (NYSE: RBOT) has announced its upcoming first quarter 2025 financial results release, scheduled for May 12, 2025, after market close. The company, which specializes in next-generation robotics technology for surgical applications, will discuss its financial performance for the period ending March 31, 2025.

Key Details:

• Conference Call Time: 4:30 p.m. Eastern Time
• Dial-in Numbers: - Domestic: +1 833-470-1428 - International: +1 404-975-4839
• Access Code: 316641

Investors and interested parties can access the live and archived webcast of the event through the company's investor relations website at investor.vicarioussurgical.com. The company's mission focuses on improving lives through the transformation of robotic surgery.

Vicarious Surgical (NYSE: RBOT) has received a notice from the NYSE on April 10, 2025, indicating non-compliance with continued listing standards. The company failed to maintain both a 30-day average market capitalization and stockholders' equity above $50 million, with market cap averaging approximately $47.4 million.

The company has 45 days to submit a compliance plan to the NYSE, detailing actions to meet requirements within an 18-month cure period. During this time, RBOT stock will continue trading with a '.BC' (below criteria) designation. If the plan is not submitted timely or accepted, NYSE will initiate delisting proceedings.

The notice does not affect daily operations or SEC reporting obligations. The company is evaluating options to regain compliance with NYSE listing standards.

Vicarious Surgical (NYSE: RBOT) announced that Company President Randy Clark will transition to a Board Member role, effective April 25, 2025. As President, Clark led key business functions including product development, operations, clinical regulatory, quality affairs, and human resources.

During his tenure, Clark made significant contributions by:

• Developing manufacturing capabilities and strengthening supply chain
• Establishing key partnerships
• Implementing personnel realignment
• Streamlining business processes
• Formalizing workflows and standardizing procedures

CEO Adam Sachs acknowledged Clark's role in building a strong foundation for future growth. Clark will continue to provide strategic guidance as a Board member, ensuring his expertise remains available to the company while allowing for leadership evolution aligned with strategic and capital needs.

Vicarious Surgical (NYSE: RBOT) has reported its Q4 and full year 2024 financial results, marking significant progress with the completion of Version 1.0 System integration. The company expanded strategic partnerships with LSU Health New Orleans, Temple Health, and University of Illinois Health, while preparing for first clinical use in 2025.

Financial highlights for Q4 2024 include operating expenses of $15.0 million (down 3% YoY), with a GAAP net loss of $13.9 million ($2.36 per share). Full year 2024 saw operating expenses of $66.6 million (17% decrease YoY) and a GAAP net loss of $63.2 million ($10.74 per share).

The company ended 2024 with $49.1 million in cash and investments, achieving its 2024 cash burn guidance. For 2025, Vicarious Surgical has set a cash burn guidance of approximately $50 million. The company has appointed Sarah Romano as CFO, effective April 1st, 2025.